Maravai LifeSciences Holdings, Inc. (MRVI) Price Prediction 2026–2050

Maravai LifeSciences Holdings, Inc. is a life sciences company that provides products that enable the development of drug therapies, vaccines, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.

The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services.

This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies.

Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.

Maravai LifeSciences Holdings, Inc. (MRVI) is a life sciences company with a current price of $5.76 and a market capitalization of $2.12B. It ranks 1994 by market cap, placing it among smaller capitalization stocks.

The stock atmosphere reflects a neutral to bullish trajectory as reflected in the annual forecast. The near-term forecast for 2026 shows an average price at $5.76, with a neutral sentiment, suggesting a baseline level around today’s price. Beyond 2026, the forecast envisions sustained upside, with the average price rising to $6.99 in 2027 and climbing further toward the mid to high single digits by 2030 and above in later years, including a long-term peak in 2050.

The multi-year forecast shows meaningful upside across the horizon. The 2030 average price is $13.34 with a bullish sentiment and a 131.5 ROI. The 2040 forecast presents an average of $37.49 with a max of $62.13 and a 550.8 ROI, underpinning strong longer-term upside.

The 2050 outlook extends to an average of $90.53 with a max of $163.55 and a 1471.7 ROI, highlighting substantial growth potential over the long term. These projections suggest a steadily rising valuation if the underlying drivers align with the forecast, but they remain estimates and are not guaranteed. Risks include market fluctuation, sector dynamics, and external factors that could affect performance relative to these targets.